SCHEMBL2503872

SCHEMBL2503872

CCCCCCCNC(=O)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O

nearest known ligand 0.45

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.45
MAPK1 P28482 1/20 0.44
GBA1 P04062 1/20 0.42
BCHE P06276 1/20 0.40
PYGB P11216 2/20 0.39
GJB2 P29033 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7879164 0.86 MAPK1 (0.46) EPHX1MAPK1GBA1PYGBGJB2
SCHEMBL2503874 0.83 MAPK1 (0.50) EPHX1MAPK1GBA1PYGBGJB2
SCHEMBL2200260 0.80 TK2 (0.51)
SCHEMBL2200265 0.80 TK2 (0.51)
SCHEMBL5425891 0.80 TK2 (0.51)
SCHEMBL2199753 0.80 TK2 (0.51)
SCHEMBL2199758 0.80 TK2 (0.51)
SCHEMBL3791687 0.80 TK2 (0.51)
SCHEMBL9252047 0.80 TK2 (0.51)
SCHEMBL27938374 0.80 TK2 (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7416843-B2 Removing aurintricarboxylic acid (ATA), a reverse transcriptase inhibitor, from a blood sample containing ATA and a chaotropic salt for nucleic acid extraction by using urea and diethylenetriaminepentaacetate; high speed analysis by aggregationg fibrin to confine pathogens to extract pathogen DNA UNIVERSITY OF SOUTH FLORIDA (US) 2008-08-26 US claimed
EP-3328992-A1 METHODS AND DEVICES FOR THE PRODUCTION OF DECELLULARISED TISSUE SCAFFOLDS UCL Business PLC (GB) 2018-06-06 EP disclosed
EP-3270897-A1 IMMUNOGENIC COMPOSITIONS FOR USE IN VACCINATION AGAINST BORDETELLA The Regents Of The University Of Michigan (US) 2018-01-24 EP disclosed
WO-2017017474-A1 METHODS AND DEVICES FOR THE PRODUCTION OF DECELLULARISED TISSUE SCAFFOLDS UCL BUSINESS PLC (GB) 2017-02-02 WO disclosed
WO-2016154010-A1 IMMUNOGENIC COMPOSITIONS FOR USE IN VACCINATION AGAINST BORDETELLA MAKIDON PAUL (US) 2016-09-29 WO disclosed
WO-2015085143-A2 THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS STC.UNM (US) 2015-06-11 WO disclosed
US-8962243-B2 Post protein hydrolysis removal of a potent ribonuclease inhibitor and the enzymatic capture of DNA UNIVERSITY OF SOUTH FLORIDA (US) 2015-02-24 US disclosed
WO-2013138520-A1 COMPOSITION AND SYSTEM FOR TRANSDERMAL DELIVERY UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-09-19 WO disclosed
US-20130130302-A1 POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA UNIVERSITY OF SOUTH FLORIDA (US) 2013-05-23 US disclosed
US-20130122509-A1 POST PROTEIN HYDROLYSIS REMOVAL OF A POTENT RIBONUCLEASE INHIBITOR AND THE ENZYMATIC CAPTURE OF DNA UNIVERSITY OF SOUTH FLORIDA (US) 2013-05-16 US disclosed
EP-2376089-A1 CANCER VACCINE COMPOSITIONS AND METHODS OF USING THE SAME The Regents of the University of Michigan (US) 2011-10-19 EP disclosed
US-20100330596-A1 LIPOPROTEIN SURFACTANT ROCHE DIABETES CARE, INC. 2010-12-30 US disclosed
WO-2010057197-A1 CANCER VACCINE COMPOSITIONS AND METHODS OF USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-05-20 WO disclosed
EP-2164982-A2 LIPOPROTEIN SURFACTANT F.HOFFMANN-LA ROCHE AG (CH) 2010-03-24 EP disclosed
WO-2008152380-A2 LIPOPROTEIN SURFACTANT OXFORD BIOSENSORS LIMITED (GB) 2008-12-18 WO disclosed